BAZ2B
Overview
BAZ2B (Bromodomain And AT-Rich Interaction Domain 2B) encodes a chromatin-remodeling factor belonging to the bromodomain-containing protein family. It is involved in chromatin organization and transcriptional regulation. In cancer genomics, BAZ2B has been identified as a recurrently mutated gene in chronic lymphocytic leukemia (CLL), where it contributes to the chromatin modification pathway that is disrupted in a subset of cases.
Alterations observed in the corpus
- BAZ2B identified as a chromatin modification driver in CLL in a 538-sample whole-exome sequencing study of 538 CLL cases (278 from the prospective CLL8 trial); classified in the chromatin modification pathway alongside ASXL1 and IKZF3 PMID:26466571.
Cancer types (linked)
- CLLSLL: Recurrently mutated chromatin modification driver in CLL identified from 538-sample WES; 44 putative CLL driver genes were identified, with BAZ2B grouped in the chromatin modification pathway PMID:26466571.
Co-occurrence and mutual exclusivity
- BAZ2B mutations co-occur with other chromatin modification pathway drivers in CLL, including ASXL1 and IKZF3; the study reports 91.1% of CLLs harbor at least one driver across all 55 driver events PMID:26466571.
Therapeutic relevance
- No specific therapeutic agents targeting BAZ2B are reported in this corpus. Its classification as a chromatin modification driver in CLL suggests potential interest for epigenetic therapeutic strategies.
Open questions
- The exact mutation frequency and clinical outcome associations for BAZ2B alone (distinct from the chromatin modification pathway group) were not reported as a standalone PFS predictor in the CLL8 trial data.
Sources
This page was processed by crosslinker on 2026-05-14.